{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-012932","form_type":"8-K","ticker":null,"cik":"0001827506","company_name":"Tourmaline Bio, Inc.","filed_at":"2023-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.932536+00:00","generated_at":"2026-06-17T02:07:33.429256+00:00","sec_items":["2.05","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Talaris eliminates ~95% of remaining workforce; CEO and three other executives depart","bullets":["April 2023 reduction of ~80 employees (95% of remaining staff); total severance costs estimated at $8.7M through Q2 2023.","CEO Scott Requadt, CMO Nancy Krieger, CTO Michael Zdanowski, and CHRO Andrew Farnsworth all leaving company.","CFO Mary Kay Fenton enters retention agreement; eligible for cash bonus upon strategic transaction or liquidation.","Prior February reduction cut ~1/3 of workforce; company continues evaluating strategic alternatives.","Reduction substantially complete by May 26, 2023; WARN Act severance provided."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-012932","json":"https://secwatch.observer/filing/0000950170-23-012932.json","markdown":"https://secwatch.observer/filing/0000950170-23-012932.md","text":"https://secwatch.observer/filing/0000950170-23-012932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/tals-20230414.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:07:33.429256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a179b16d1","claim":"Scott Requadt resigned as President and Chief Executive Officer at Tourmaline Bio, Inc..","evidence_excerpt":"Scott Requadt, President and Chief Executive Officer, effective May 26, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"34af9efdff","claim":"Andrew Farnsworth resigned as Chief Human Resources Officer at Tourmaline Bio, Inc..","evidence_excerpt":"Andrew Farnsworth, Chief Human Resources Officer, effective May 26, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Human Resources Officer"}],"fact_type":"executive_change"},{"claim_id":"6d85dc1d7e","claim":"Michael Zdanowski resigned as Chief Technology Officer at Tourmaline Bio, Inc..","evidence_excerpt":"Michael Zdanowski, Chief Technology Officer, effective April 28, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Technology Officer"}],"fact_type":"executive_change"},{"claim_id":"a316859973","claim":"Nancy Krieger resigned as Chief Medical Officer at Tourmaline Bio, Inc..","evidence_excerpt":"Nancy Krieger, Chief Medical Officer, effective April 28, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"62a206733a25061c2e515b7896bf20e22523c8e0","claim":"Tourmaline Bio, Inc. announced a restructuring with charges of approximately $5.8 million (approximately 80 additional employees, or approximately 95% of the Company's remaining workforce).","evidence_excerpt":"the Company estimates it will incur cash-based severance and other employee termination-related costs of approximately $5.8 million in the second quarter of 2023 related to the April Reduction in Force","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $5.8 million"},{"label":"Headcount","value":"approximately 80 additional employees, or approximately 95% of the Company's remaining workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}